Prolactin and Its Altered Action in Alzheimer’s Disease and Parkinson’s Disease

Background: Prolactin (PRL) is one of the most diverse pituitary hormones and is known to modulate normal neuronal function and neurodegenerative conditions. Many studies have described the influence that PRL has on the central nervous system and addressed its contribution to neurodegeneration, but...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuroendocrinology 2022-05, Vol.112 (5), p.427-445
Hauptverfasser:	Duc Nguyen, Hai, Pal Yu, Byung, Hoang, Ngoc Hong Minh, Jo, Won Hee, Young Chung, Hae, Kim, Min-Sun
Format:	Artikel
Sprache:	eng
Schlagworte:	Advertising executives Alzheimer Disease Alzheimer's disease At the Cutting Edge Humans Neurons Neurophysiology Parkinson Disease Prolactin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	445
container_issue	5
container_start_page	427
container_title	Neuroendocrinology
container_volume	112
creator	Duc Nguyen, Hai Pal Yu, Byung Hoang, Ngoc Hong Minh Jo, Won Hee Young Chung, Hae Kim, Min-Sun
description	Background: Prolactin (PRL) is one of the most diverse pituitary hormones and is known to modulate normal neuronal function and neurodegenerative conditions. Many studies have described the influence that PRL has on the central nervous system and addressed its contribution to neurodegeneration, but little is known about the mechanisms responsible for the effects of PRL on neurodegenerative disorders, especially on Alzheimer’s disease (AD) and Parkinson’s disease (PD). Summary: We review and summarize the existing literature and current understanding of the roles of PRL on various PRL aspects of AD and PD. Key Messages: In general, PRL is viewed as a promising molecule for the treatment of AD and PD. Modulation of PRL functions and targeting of immune mechanisms are needed to devise preventive or therapeutic strategies.
doi_str_mv	10.1159/000517798
format	Article
fullrecord	<record><control><sourceid>gale_karge</sourceid><recordid>TN_cdi_gale_infotracacademiconefile_A709902454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A709902454</galeid><sourcerecordid>A709902454</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-9963c5089f575efd91aa9805e3dfbfd5ca6620618762614d592e9bd88861910c3</originalsourceid><addsrcrecordid>eNpt0c9LHDEUB_BQFF2th96LDHixh9H8mMwkx8FaXRCVqueQTV7W6PzYJrPQevLf6L_nX9Ksq0uFJYfAe58XXvgi9IXgI0K4PMYYc1JVUnxCI1JQlmMiiw00wpiKnAnGt9FOjA-JUcnoFtpmBaFlSfEI3VyHvtFm8F2mO5uNh5jVzQABbFanat9lqVM3T_fgWwgvz39j9t1H0BFe_bUOj76Lffd_5zPadLqJsPd276K7H6e3J-f5xdXZ-KS-yE1R4SGXsmSGYyEdrzg4K4nWUmAOzLqJs9zoxYolEVVJS1JYLinIiRVClEQSbNguOly-Owv9rznEQbU-Gmga3UE_j4rygjAiKWGJHizpVDegfOf6IWiz4KqusJSYFrxI6miNSsdC603fgfOp_mHg24eBZAb4PUz1PEY1vvm51prQxxjAqVnwrQ5_FMFqEaNaxZjs_tvP5pMW7Eq-55bA1yV41GEKYQVW8wdr25enl0uhZtaxf0lDqeQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2541319213</pqid></control><display><type>article</type><title>Prolactin and Its Altered Action in Alzheimer’s Disease and Parkinson’s Disease</title><source>MEDLINE</source><source>Karger Journals</source><creator>Duc Nguyen, Hai ; Pal Yu, Byung ; Hoang, Ngoc Hong Minh ; Jo, Won Hee ; Young Chung, Hae ; Kim, Min-Sun</creator><creatorcontrib>Duc Nguyen, Hai ; Pal Yu, Byung ; Hoang, Ngoc Hong Minh ; Jo, Won Hee ; Young Chung, Hae ; Kim, Min-Sun</creatorcontrib><description>Background: Prolactin (PRL) is one of the most diverse pituitary hormones and is known to modulate normal neuronal function and neurodegenerative conditions. Many studies have described the influence that PRL has on the central nervous system and addressed its contribution to neurodegeneration, but little is known about the mechanisms responsible for the effects of PRL on neurodegenerative disorders, especially on Alzheimer’s disease (AD) and Parkinson’s disease (PD). Summary: We review and summarize the existing literature and current understanding of the roles of PRL on various PRL aspects of AD and PD. Key Messages: In general, PRL is viewed as a promising molecule for the treatment of AD and PD. Modulation of PRL functions and targeting of immune mechanisms are needed to devise preventive or therapeutic strategies.</description><identifier>ISSN: 0028-3835</identifier><identifier>EISSN: 1423-0194</identifier><identifier>DOI: 10.1159/000517798</identifier><identifier>PMID: 34126620</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Advertising executives ; Alzheimer Disease ; Alzheimer's disease ; At the Cutting Edge ; Humans ; Neurons ; Neurophysiology ; Parkinson Disease ; Prolactin</subject><ispartof>Neuroendocrinology, 2022-05, Vol.112 (5), p.427-445</ispartof><rights>2021 S. Karger AG, Basel</rights><rights>2021 S. Karger AG, Basel.</rights><rights>COPYRIGHT 2022 S. Karger AG</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-9963c5089f575efd91aa9805e3dfbfd5ca6620618762614d592e9bd88861910c3</citedby><cites>FETCH-LOGICAL-c470t-9963c5089f575efd91aa9805e3dfbfd5ca6620618762614d592e9bd88861910c3</cites><orcidid>0000-0001-8419-7784 ; 0000-0001-6875-4050 ; 0000-0001-9952-0038</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34126620$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Duc Nguyen, Hai</creatorcontrib><creatorcontrib>Pal Yu, Byung</creatorcontrib><creatorcontrib>Hoang, Ngoc Hong Minh</creatorcontrib><creatorcontrib>Jo, Won Hee</creatorcontrib><creatorcontrib>Young Chung, Hae</creatorcontrib><creatorcontrib>Kim, Min-Sun</creatorcontrib><title>Prolactin and Its Altered Action in Alzheimer’s Disease and Parkinson’s Disease</title><title>Neuroendocrinology</title><addtitle>Neuroendocrinology</addtitle><description>Background: Prolactin (PRL) is one of the most diverse pituitary hormones and is known to modulate normal neuronal function and neurodegenerative conditions. Many studies have described the influence that PRL has on the central nervous system and addressed its contribution to neurodegeneration, but little is known about the mechanisms responsible for the effects of PRL on neurodegenerative disorders, especially on Alzheimer’s disease (AD) and Parkinson’s disease (PD). Summary: We review and summarize the existing literature and current understanding of the roles of PRL on various PRL aspects of AD and PD. Key Messages: In general, PRL is viewed as a promising molecule for the treatment of AD and PD. Modulation of PRL functions and targeting of immune mechanisms are needed to devise preventive or therapeutic strategies.</description><subject>Advertising executives</subject><subject>Alzheimer Disease</subject><subject>Alzheimer's disease</subject><subject>At the Cutting Edge</subject><subject>Humans</subject><subject>Neurons</subject><subject>Neurophysiology</subject><subject>Parkinson Disease</subject><subject>Prolactin</subject><issn>0028-3835</issn><issn>1423-0194</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0c9LHDEUB_BQFF2th96LDHixh9H8mMwkx8FaXRCVqueQTV7W6PzYJrPQevLf6L_nX9Ksq0uFJYfAe58XXvgi9IXgI0K4PMYYc1JVUnxCI1JQlmMiiw00wpiKnAnGt9FOjA-JUcnoFtpmBaFlSfEI3VyHvtFm8F2mO5uNh5jVzQABbFanat9lqVM3T_fgWwgvz39j9t1H0BFe_bUOj76Lffd_5zPadLqJsPd276K7H6e3J-f5xdXZ-KS-yE1R4SGXsmSGYyEdrzg4K4nWUmAOzLqJs9zoxYolEVVJS1JYLinIiRVClEQSbNguOly-Owv9rznEQbU-Gmga3UE_j4rygjAiKWGJHizpVDegfOf6IWiz4KqusJSYFrxI6miNSsdC603fgfOp_mHg24eBZAb4PUz1PEY1vvm51prQxxjAqVnwrQ5_FMFqEaNaxZjs_tvP5pMW7Eq-55bA1yV41GEKYQVW8wdr25enl0uhZtaxf0lDqeQ</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Duc Nguyen, Hai</creator><creator>Pal Yu, Byung</creator><creator>Hoang, Ngoc Hong Minh</creator><creator>Jo, Won Hee</creator><creator>Young Chung, Hae</creator><creator>Kim, Min-Sun</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8419-7784</orcidid><orcidid>https://orcid.org/0000-0001-6875-4050</orcidid><orcidid>https://orcid.org/0000-0001-9952-0038</orcidid></search><sort><creationdate>20220501</creationdate><title>Prolactin and Its Altered Action in Alzheimer’s Disease and Parkinson’s Disease</title><author>Duc Nguyen, Hai ; Pal Yu, Byung ; Hoang, Ngoc Hong Minh ; Jo, Won Hee ; Young Chung, Hae ; Kim, Min-Sun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-9963c5089f575efd91aa9805e3dfbfd5ca6620618762614d592e9bd88861910c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Advertising executives</topic><topic>Alzheimer Disease</topic><topic>Alzheimer's disease</topic><topic>At the Cutting Edge</topic><topic>Humans</topic><topic>Neurons</topic><topic>Neurophysiology</topic><topic>Parkinson Disease</topic><topic>Prolactin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Duc Nguyen, Hai</creatorcontrib><creatorcontrib>Pal Yu, Byung</creatorcontrib><creatorcontrib>Hoang, Ngoc Hong Minh</creatorcontrib><creatorcontrib>Jo, Won Hee</creatorcontrib><creatorcontrib>Young Chung, Hae</creatorcontrib><creatorcontrib>Kim, Min-Sun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>MEDLINE - Academic</collection><jtitle>Neuroendocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Duc Nguyen, Hai</au><au>Pal Yu, Byung</au><au>Hoang, Ngoc Hong Minh</au><au>Jo, Won Hee</au><au>Young Chung, Hae</au><au>Kim, Min-Sun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolactin and Its Altered Action in Alzheimer’s Disease and Parkinson’s Disease</atitle><jtitle>Neuroendocrinology</jtitle><addtitle>Neuroendocrinology</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>112</volume><issue>5</issue><spage>427</spage><epage>445</epage><pages>427-445</pages><issn>0028-3835</issn><eissn>1423-0194</eissn><abstract>Background: Prolactin (PRL) is one of the most diverse pituitary hormones and is known to modulate normal neuronal function and neurodegenerative conditions. Many studies have described the influence that PRL has on the central nervous system and addressed its contribution to neurodegeneration, but little is known about the mechanisms responsible for the effects of PRL on neurodegenerative disorders, especially on Alzheimer’s disease (AD) and Parkinson’s disease (PD). Summary: We review and summarize the existing literature and current understanding of the roles of PRL on various PRL aspects of AD and PD. Key Messages: In general, PRL is viewed as a promising molecule for the treatment of AD and PD. Modulation of PRL functions and targeting of immune mechanisms are needed to devise preventive or therapeutic strategies.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>34126620</pmid><doi>10.1159/000517798</doi><tpages>19</tpages><orcidid>https://orcid.org/0000-0001-8419-7784</orcidid><orcidid>https://orcid.org/0000-0001-6875-4050</orcidid><orcidid>https://orcid.org/0000-0001-9952-0038</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0028-3835
ispartof	Neuroendocrinology, 2022-05, Vol.112 (5), p.427-445
issn	0028-3835 1423-0194
language	eng
recordid	cdi_gale_infotracacademiconefile_A709902454
source	MEDLINE; Karger Journals
subjects	Advertising executives Alzheimer Disease Alzheimer's disease At the Cutting Edge Humans Neurons Neurophysiology Parkinson Disease Prolactin
title	Prolactin and Its Altered Action in Alzheimer’s Disease and Parkinson’s Disease
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T12%3A27%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolactin%20and%20Its%20Altered%20Action%20in%20Alzheimer%E2%80%99s%20Disease%20and%20Parkinson%E2%80%99s%20Disease&rft.jtitle=Neuroendocrinology&rft.au=Duc%20Nguyen,%20Hai&rft.date=2022-05-01&rft.volume=112&rft.issue=5&rft.spage=427&rft.epage=445&rft.pages=427-445&rft.issn=0028-3835&rft.eissn=1423-0194&rft_id=info:doi/10.1159/000517798&rft_dat=%3Cgale_karge%3EA709902454%3C/gale_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2541319213&rft_id=info:pmid/34126620&rft_galeid=A709902454&rfr_iscdi=true